Target type: biologicalprocess
Any process that stops, prevents, or reduces the frequency, rate or extent of neuroblast migration. [PMID:23149556]
Negative regulation of neuroblast migration is a crucial process for the precise organization and function of the nervous system. It ensures that neuroblasts, immature nerve cells, migrate to their correct locations, forming the intricate network of neural connections. This complex process involves a tightly regulated interplay of signaling pathways, molecular cues, and cellular interactions.
**Key Molecular Players:**
* **Guidance Cues:** Neuroblasts navigate their journey by following gradients of guidance cues, such as netrins, semaphorins, and Slits. These molecules bind to receptors on the surface of neuroblasts, triggering intracellular signaling cascades that direct their movement.
* **Adhesion Molecules:** Cell adhesion molecules, including cadherins and integrins, mediate cell-cell and cell-matrix interactions, respectively. These molecules play a critical role in maintaining the integrity of migrating neuroblast chains and their adherence to the surrounding environment.
* **Cytoskeletal Components:** The cytoskeleton, composed of microtubules and actin filaments, provides the structural framework for cell shape and movement. During migration, microtubule dynamics and actin polymerization are precisely regulated to drive the extension and retraction of cell processes, facilitating directional movement.
**Mechanism of Negative Regulation:**
* **Repulsion:** Some guidance cues act as repellents, pushing neuroblasts away from certain areas. This repulsion ensures that neuroblasts avoid inappropriate paths and target regions.
* **Inhibition of Attractive Signals:** Negative regulation can also involve inhibiting the activity of attractive guidance cues, effectively reducing their influence on neuroblast movement.
* **Downregulation of Adhesion:** Decreasing the expression or activity of adhesion molecules can weaken the adhesion of neuroblasts to their environment, promoting detachment and migration.
* **Cytoskeletal Remodeling:** Modifications in the cytoskeleton can hinder the extension of cell processes or disrupt the directional movement of the neuroblast.
**Consequences of Dysregulation:**
Dysregulation of negative regulation of neuroblast migration can lead to developmental abnormalities, including:
* **Miswiring of Neural Circuits:** Neuroblasts may migrate to incorrect locations, disrupting the formation of functional neural circuits and affecting brain development.
* **Neurodevelopmental Disorders:** Defects in neuroblast migration can contribute to a range of neurodevelopmental disorders, such as autism spectrum disorder, intellectual disability, and epilepsy.
**Research Significance:**
Understanding the molecular mechanisms underlying negative regulation of neuroblast migration is essential for unraveling the complexities of brain development and for developing therapeutic strategies for neurodevelopmental disorders. Research efforts continue to focus on identifying new regulators of neuroblast migration, understanding their functions, and developing approaches to correct migration defects.'
"
Protein | Definition | Taxonomy |
---|---|---|
ATP-binding cassette sub-family C member 8 | An ATP-binding cassette sub-family C member 8 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q09428] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
diazoxide | diazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies. Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group. | benzothiadiazine; organochlorine compound; sulfone | antihypertensive agent; beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; diuretic; K-ATP channel agonist; sodium channel blocker; sympathomimetic agent; vasodilator agent |
glyburide | glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group. Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide | monochlorobenzenes; N-sulfonylurea | anti-arrhythmia drug; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor; hypoglycemic agent |
troglitazone | Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity. | chromanes; thiazolidinone | anticoagulant; anticonvulsant; antineoplastic agent; antioxidant; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; hypoglycemic agent; platelet aggregation inhibitor; vasodilator agent |
n-cyano-n'-(1,1-dimethylpropyl)-n''-(3-pyridinyl)guanidine | N-cyano-N'-(1,1-dimethylpropyl)-N''-(3-pyridinyl)guanidine: potassium channel opener | pyridines | |
repaglinide | piperidines | ||
cromakalim | Cromakalim: A potassium-channel opening vasodilator that has been investigated in the management of hypertension. It has also been tried in patients with asthma. (Martindale, The Extra Pharmacopoeia, 30th ed, p352) | ||
rosiglitazone | aminopyridine; thiazolidinediones | EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; insulin-sensitizing drug | |
mk 767 | 5-((2,4-dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)benzamide: an antihyperlipidemic agent that also functions as an insulin sensitizer, PPARalpha agonist, and PPARgamma agonist; structure in first source | ||
zeneca zd 6169 | Zeneca ZD 6169: an ATP-sensitive potassium channel opener; structure given in first source | ||
cromakalim | 1-benzopyran | ||
clamikalant | clamikalant: inhibits ATP-sensitive potassium channel; structure in first source | ||
zm226600 | ZM226600: an ATP-sensitive potassium channel opener; structure in first source | anilide | |
way 133537 | |||
ly 465608 | LY 465608: a nonthiazolidinedione agonist of both PPAR-alpha and PPAR-gamma of Ligand Pharm. and Eli Lilly | ||
bm 131246 | |||
nn 414 | NN 414: a hypoglycemic agent with insulin release modulating and potassium channel activating activities; structure in first source | ||
7-chloro-3-isopropylamino-4h-1,2,4-benzothiadiazine 1,1-dioxide | 7-chloro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide: activates ATP-sensitive potassium channels; structure in first source |